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Congenital heart disease (CHD) behaves like a complex genetic trait in most
instances. Recent advances in genomics have provided tools for uncovering
genetic variants underlying complex traits that are now being applied to study
CHD. Massively parallel DNA sequencing has shown that de novo mutations
contribute to ~10 % of severe CHD and implicated chromatin remodeling in
pathogenesis. Genome scanning methods for copy number variants (CNVs)
identify likely pathogenic genomic alterations in 10 % of infants with hypoplas-
tic left heart syndrome and related single ventricle forms of CHD. The growth
and neurocognitive development of children with CHD and those CNVs is
worse, and clinical examination is relatively insensitive for detecting those
CNVs. In sum, new opportunities for preventing and ameliorating CHD and its
comorbidities are anticipated as its genetic architecture is elaborated through the
use of state-of-the-art genomic approaches.
Keywords
Congenital heart disease • Copy number variants • Exome sequencing • Genetics
51.1 Introduction
Congenital heart defects (CHD), with an estimated incidence of 2–3 % when
bicuspid aortic valve (BAV) is included, are widely believed to have strong genetic
underpinnings. Epidemiologic studies have shown considerable consistency in the
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distribution of CHD lesions across time and geographic location. The landmark
study by Ruth Whittemore, in which she examined recurrence risks for offspring of
women with CHD, revealed a 16 % rate with a 60 % concordance in the form of
CHD between mother and child [1]. Estimates of heritability for BAV and hypo-
plastic left heart syndrome (HLHS) are 89 % and 95 %, respectively [2, 3]. Recent
studies of CHD from Denmark, where the highly organized medical system enables
population studies, have provide estimates of the relative risks of various forms of
CHD among first-degree relatives that significantly increased, often to >5
[4]. Taken as a whole, these epidemiologic findings point to genetic defects
contributing importantly to CHD etiology.
Identification of the precise mutations has been challenging [5]. We have known
for some time that a modest percentage of CHD (~5 %) is attributable to
aneuploidies such as trisomy 21. With the advent of molecular genetic approaches,
point mutations with apparently strong effects have been identified in rare families
inheriting CHD in Mendelian or near-Mendelian fashion. More recently, the role of
larger genomic events generating pathologic copy number variants (CNVs) for
CHD has become apparent. This started with the recognition of 22q11 deletions
underlying DiGeorge, Takao conotruncal face, and velocardiofacial syndromes.
Several surveys have implicated a wide range of gain and loss CNVs in various
forms of CHD.
Based on the author’s oral presentation at the 2013 Takao Symposium, two
recent studies that further elaborate the genetic etiology of CHD will be
reviewed here.
51.2 De Novo Mutations
Through recent advances in molecular genetic technologies, it is now possible to
sequence the roughly 1% of the human genome that contains the coding regions for all
genes (called the exome), representing approximately 180,000 exons and
30 megabases (Mb), in a relatively rapid and affordable manner. While exome
sequencing was initially used to discover mutations underlying Mendelian disorders,
current efforts are increasingly focusing on unraveling complex genetic traits.
The Pediatric Cardiac Genomics Consortium (PCGC) [6], a National Heart,
Lung, and Blood Institute-funded research enterprise, recently completed a first-
of-kind study to determine the role of de novo mutations in the etiology of severe
forms of CHD [7]. Exome sequencing was performed for 362 parent-offspring trios,
in which the offspring had a sporadic conotruncal defect, left ventricular outflow
track obstructive lesion, or heterotaxy, and compared to comparable data from
264 control trios. While the overall rate of de novo point and small insertion/
deletion (indel) changes was equivalent between CHD cases and controls, there
was an excess burden of protein-altering mutations in genes highly expressed
during heart development (odds ratio (OR) of 2.53). Excess mutations had a role
in 10 % of CHD cases and led to the estimate that ~400 genes underlie these birth
defects. After filtering to retain variants most likely to be deleterious (nonsense,
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splice site, and frameshift defects), the burden among CHD cases increased,
attaining an OR of 7.50.
Next, the PCGC investigators asked whether the burden of de novo protein-
altering mutations among the CHD cases preferentially targeted particular biologic
processes [7]. Indeed, they observed a highly significant enrichment of mutation
among genes encoding proteins relevant for chromatin biology, specifically the
production, removal, or reading of methylation of Lys4 of histone 3 (H3K4me)
(Fig. 51.1). The phenotypes of the eight subjects harboring H3K4me de novo
mutations were diverse, both with respect to the form of CHD and the involvement
of extracardiac tissues. In addition, two independent de novo mutations were found
in SMAD2, which encodes a protein with relevance for demethylation of Lys27 of
histone 3 (H3K27me). SMAD2 contributes to the development of the left-right
body axis; both subjects harboring SMAD2 mutations had dextrocardia with unbal-
anced complete atrioventricular canal defects with pulmonic stenosis. While the
contribution of chromatin remodeling to cardiovascular development generally and
Fig. 51.1 De novo mutations in the H3K4 and H3K27 methylation pathways. Nucleosome with
histone octamer and DNA, H3K4 methylation bound by CHD7, and H3K27 methylation and
H2BK120 ubiquitination is shown. Genes mutated in CHD that affect the production, removal, and
reading of these histone modifications are shown; genes with damaging mutations are shown in
red, and those with missense mutations are shown in blue. SMAD2 (2) indicates there are two
patients with a mutation in this gene. Genes whose products are found together in a complex are
enclosed in a box (Reprinted without modification from Ref. [7])
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certain rare genetic syndromes with CHD like Kabuki syndrome had been
recognized previously, this study exposed a far broader role in CHD pathogenesis.
The finding also suggests a fascinating potential link to other birth defects as de
novo chromatin remodeling mutations have also been implicated in autism [8].
51.3 Copy Number Variants
CNVs, which are gains or losses of DNA ranging in size from 1 kb to several Mbs,
affect roughly 10 % of the human genome [9]. CNVs are typically detected on a
genome-wide basis using SNP microarrays or array comparative genomic
hybridization (aCGH). Although differentiating pathogenic CNVs from benign
polymorphic one remains challenging, it has become clear that pathologic CNVs
contribute significantly to the pathogenesis of CHD as rare large CNVs are
observed in 5–15 % of affected individuals [10–14].
To address the issue of how pathogenic CNVs affected outcomes for children with
CHD, Carey and colleagues studied children who had previously been subjects in one
or both of two clinical trials undertaken by the National Heart, Lung, and Blood
Institute-funded Pediatric Heart Network [15]. The two studies were the Infants with
Single Ventricle (ISV) and Single Ventricle Reconstruction (SVR) trials, both focus-
ing primarily on infants with HLHS. Carey et al. used aCGH to identify CNVs in
223 subjects from the ISV and SVR trials for whom genomic DNA was available.
Because the DNA samples were procured late in those trials, subjects who died earlier,
particularly perioperatively, could not be studied. For the CNV work, CNVs were
300 kb and not identified as genetic polymorphisms based on existing databases.
Carey and co-workers observed pathogenic CNVs in 13.9 % of the children,
which was significantly more than the 4.4 % rate in the controls (preexisting data
from blood samples from subjects with solid cancers from The Cancer Genome
Atlas project) [15]. For the CHD cases, there was a roughly 4:1 ratio of duplications
to deletions and the median sizes were 674 kb and 1.5 Mb, respectively. Parental
genomic DNAs were available for 12 of the subjects with pathogenic CNVs;
analysis of those showed that slightly more than have of the pathogenic CNVs
were inherited.
For the ISV and SVR studies, careful assessment of growth (weight-, height- and
head circumference-for-age z-scores) and neurocognitive function (Mental Devel-
opmental Index (MDI) and Psychomotor Developmental Index (PDI) measured
with the Bayley Scales of Infant Development II) were determined at 14 months of
age [15]. Comparison of the CHD subjects harboring pathogenic CNVs to those
who did not revealed that the former were significantly shorter by an average of
0.65 z-score. Subgroup analysis showed that those with deletion CNVs had signifi-
cantly lower PDI scores.
Among the 31 pathogenic CNVs found among the CHD subjects, 13 had
previously been associated with genomic disorders. The children harboring these
known CNVs had the worst outcomes with globally reduced neurocognitive devel-
opment (MDI and PDI) as well as the slowest growth (Table 51.1).
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Finally, Carey and co-workers looked at the sensitivity of clinical examination in
detecting children with CHD and pathogenic CNVs, which was possible for the
subjects from the SVR study [15]. Of 116 children examined, 3.4 % were diagnosed
with a defined genetic syndrome, none associated with a pathogenic CNV, and 25 %
had one or more dysmorphic features and/or extracardiac malformations, which
were not enriched among those with CNVs. Most strikingly, more than 70 % of the
children with CNVs previously associated with genomic disorders had no dysmor-
phic feature or extracardiac anomaly. Taken as a whole, this analysis showed that
clinical examination was relatively insensitive for determining which children with
CHD harbored pathogenic CNVs.
The findings from this study support the routine use of CNV testing in newborns
with single ventricle forms of CHD to enable better prognostication and early
intervention. Similarly, the poorer linear growth associated with all pathogenic
CNVs, the worse neurocognitive outcomes with deletions, and particularly the
globally poor outcomes with CNVs associated with known genomic disorders
could impact clinical trial outcomes depending on the designated endpoints.
51.4 Future Directions
Recent advances in genomics have enabled the elucidation of the architecture of
CHD genetics. As that project proceeds, the next challenge will be translating those
gene discoveries into actionable clinical approaches. Improved prognostication
with respect to the heart disease and extracardiac comorbidities can be used most
immediately. Finding strategies that reduce CHD incidence or alter its natural
Table 51.1 Fourteen-month outcomes for subgroups based on genetic examination
Na MDI PDI Weight Z Length Z HC Z
CNV- Syndrome- Dysmorphic-
Extracardiac-
69 89.1 77.5 0.71 1.13 0.34
(18.0) (20.2) (1.07) (1.32) (1.24)
CNV+ 14 85.4 65.1* 0.94 1.61 0.04
(20.1) (17.6) (0.88) (1.08) (1.38)
CNV+ or syndrome 18 83.2 67.9* 1.19* 1.99* 0.16
(18.7) (19.4) (1.11) (1.73) (1.27)
Dysmorphic/extracardiac 29 89.3 78.1 0.63 1.18 0.10
(18.1) (20.0) (1.25) (1.30) (1.28)
CNV syndrome 98 89.4 77.8 0.73 1.18 0.25
(17.5) (19.8) (1.10) (1.43) (1.32)
All data shown as mean (standard deviation)
MDI mental developmental index, PDI psychomotor developmental index, Weight Z weight-for-
age Z score at 14 months, Length Z length-for-age Z score at 14 months, HC Z head circumference
Z score at 14 months
*p< 0.05 compared to CNV/syndrome/dysmorphic/extracardiac
aSize of each cohort. Incomplete data for outcomes resulted in lower Ns. Reprinted without
modification from Ref. [15]
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history will require the elucidation of pathogeneses, and a careful balancing of
potential benefits with adverse effects as fundamental biological process like
chromatin remodeling will probably predominate.
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